Reprogramming immune cells to improve tolerance in autoimmune diseases
Reprogramming of Regulatory T cells to Promote Immune Tolerance
This study is looking at how to make certain immune cells work better to help people with autoimmune diseases, with the hope of finding new treatments that can lessen their symptoms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Children's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10839800 on NIH RePORTER |
What this research studies
This research focuses on enhancing the function of regulatory T cells, which are crucial for maintaining immune tolerance and preventing autoimmune diseases. By investigating the role of the Foxp3 protein and its impact on Treg cell differentiation, the study aims to identify ways to restore the suppressive functions of these cells in patients with autoimmune conditions. The approach involves manipulating metabolic pathways within these cells to improve their ability to regulate the immune response. Patients may benefit from new therapies that could reduce the severity of autoimmune disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with autoimmune disorders, particularly those with compromised regulatory T cell function.
Not a fit: Patients with non-autoimmune conditions or those whose immune system functions normally may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that enhance immune tolerance and reduce the impact of autoimmune diseases.
How similar studies have performed: Previous research has shown promise in reprogramming immune cells for therapeutic purposes, indicating that this approach may lead to significant advancements in treating autoimmune diseases.
Where this research is happening
Boston, United States
- Boston Children's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Charbonnier, Louis-Marie — Boston Children's Hospital
- Study coordinator: Charbonnier, Louis-Marie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.